Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is anA Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE): More Information
The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment ofFor Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma: More Information
Active, not recruiting
The purpose of this Phase 2, open-label, single-arm study is to determine the safety and theFor Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression: More Information
The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety andFor Patients With Recurrent Malignant Glioma: More Information
The safety and efficacy of the investigational use of this product has not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.